CHESS is a pharmacovigiliance program to monitor the safety of treaments for people with inherited bleeding disorders in Canada.
Hemophilia treatment centres report adverse events directly to the CHESS website and regular surveillance reports are produced.
Link: http://www.chess-ca.org/
This is a research line aiming to the discovery of actionable mechanism to improve the prevention
and eradication of inhibitors. The main laboratory for this line is located at the Department of Pharmacology of the University of Perugia (prof Paolo
Puccetti, prof Francesca Fallarino, Dr Davide Matino). The research line involves both in vitro, in vivo and ex-vivo experiments, and is supported by
several centers of the Associazione Italiana Centri Emofilia. The research has been supported by unrestricted peer review funds from the Bayer Award
Program (Davide Matino and Francesca Fallarino), Italina Ministry of Health (Davide Matino), Telethon (Francesca Fallarino).
A first results of this exciting research line has been recently published on Nature:
http://www.ncbi.nlm.nih.gov/pubmed/24930766
This is an exciting innovative project where the McGrade working group, led by Holger Schunemann,
is supporting the development of guidelines for the management of hemophilia fostered by the National Hemophilia Foundation.
More details can be found on the website of the partner organization. Further details on the McGrade unit and activity can be found at:
http://www.hemophilia.org/newsroom/medical-news/nhf-and-McMaster-University-Collaborate-on-Clinical-Practice-Guidelines-for-Hemophilia-Care-Models